Vaccine with beta-glucan and GM-CSF for neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial is testing whether adding a vaccine to a substance called beta-glucan (which may help the immune system) and a growth factor drug called GM-CSF can help prevent high-risk neuroblastoma from coming back. You would receive these as an injection or IV. The study is for people whose cancer is in remission or has responded well to prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk neuroblastoma, as defined by your doctor, and you are in your first complete remission (no signs of cancer) or later remissions after treatment.
- You have recovered from side effects of prior treatments and have adequate blood counts and organ function (kidneys, liver, heart, lungs).
- You have not had an allergy to any of the vaccine components (like KLH, QS-21, OPT-821, or beta-glucan) or to GM-CSF.
- You must have a negative pregnancy test if you can get pregnant and agree to use birth control.
- You have completed any prior systemic therapy at least 21 days before the first vaccination and are within 180 days of your last systemic therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine combined with beta-glucan, a natural immune booster, to help keep high-risk neuroblastoma from coming back. It is for patients who have finished standard treatment and achieved complete remission.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests a new combination of medicines for children with high-risk neuroblastoma that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This trial tests whether a stem cell transplant from a donor can help children with high-risk neuroblastoma. It aims to replace damaged bone marrow with healthy cells to fight the cancer.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.